期刊文献+

可溶性纤维介素蛋白2对肝细胞肝癌患者术后早期复发的预测价值 被引量:1

Predictive Value of Soluble Interleukin-2 in Early Postoperative Recurrence of Hepatocellular Carcinoma Patients
下载PDF
导出
摘要 肝细胞肝癌是最常见的恶性肿瘤之一[1]。目前肝细胞肝癌患者术后复发转移是一个难题,寻找有效指标来识别肝癌切除术后的复发转移,成为临床上肝癌研究新的热点[2-4]。可溶性纤维介素蛋白2(soluble fibrinogen-like protein 2,sFGL2)是一个参与各种免疫过程的重要效应分子,包括抗原呈递、免疫抑制和细胞凋亡。越来越多的证据表明,sFGL2参与多种疾病的发病机制,如肿瘤生长、病毒感染、同种异体移植排斥和自身免疫疾病[5-9]。本研究回顾性分析了111例肝细胞肝癌患者术前sFGL2水平与患者切除术后早期复发情况的相关性,并评估其临床价值。
作者 姚程飞 沈晓燕 徐敏敏 YAO Chengfei;SHEN Xiaoyan;XU Minmin
出处 《浙江中西医结合杂志》 2020年第8期659-662,共4页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献1

二级参考文献189

  • 1Jian-Yong Lei,Wen-Tao Wang,Lu-Nan Yan.“Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma:A single-center analysis in China's Mainland[J].World Journal of Gastroenterology,2013,19(44):8093-8098. 被引量:5
  • 2F. Y.Yao,L.Xiao,N. M.Bass,R.Kerlan,N. L.Ascher,J. P.Roberts.Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging[J].American Journal of Transplantation.2007(11)
  • 3Pierre-Alain Clavien,Mickael Lesurtel,Patrick MM Bossuyt,Gregory J Gores,Bernard Langer,Arnaud Perrier.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncology . 2012 (1)
  • 4Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 5Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 6European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 7Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 8F.Xavier Bosch,Josepa Ribes,Mireia Díaz,Ramon Cléries.Primary liver cancer: Worldwide incidence and trends[J].Gastroenterology.2004(5)
  • 9Francesca Bravi,Cristina Bosetti,Alessandra Tavani,Silvano Gallus,Carlo La Vecchia.Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-Analysis[J].Clinical Gastroenterology and Hepatology.2013
  • 10E. Terzi,R. Golfieri,F. Piscaglia,M. Galassi,A. Dazzi,S. Leoni,E. Giampalma,M. Renzulli,L. Bolondi.Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”[J].Journal of Hepatology.2012(6)

共引文献51

同被引文献16

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部